title: Phase II trial of neoadjuvant chemotherapy with XELOX plus bevacizumab for locally advanced rectal cancer.
abstract: In Western countries, the standard treatment for locally advanced rectal cancer is preoperative chemoradiotherapy followed by total mesorectal excision. On the other hand, in Japan, treatment results without radiotherapy are by no means inferior; therefore, extrapolation of results of preoperative treatment in Western countries to Japan is controversial. We consider that survival may be improved by preoperative treatment with new anticancer agents as they are expected not only to decrease the local recurrence rate but also to prevent distant metastases. We are conducting a multicentre Phase II study to evaluate the safety and efficacy of neoadjuvant chemotherapy using XELOX plus bevacizumab without radiotherapy in patients with locally advanced rectal cancer. The primary endpoint of the study is treatment compliance. Secondary endpoints are overall survival, disease-free survival, local recurrence-free survival, objective response rate, R0 resection rate and adverse events. Thirty patients are required for this study.
authors.affiliation: Division of Surgical Oncology, Department of Surgery, Nagoya Graduate School of Medicine, 65, Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan.
authors.forename: Keisuke
authors.initials: K
authors.lastname: Uehara
authors.forename: Seiji
authors.initials: S
authors.lastname: Ishiguro
authors.forename: Eiji
authors.initials: E
authors.lastname: Sakamoto
authors.forename: Atsuyuki
authors.initials: A
authors.lastname: Maeda
authors.forename: Masaya
authors.initials: M
authors.lastname: Inoue
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Tojima
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Naoki
authors.initials: N
authors.lastname: Omiya
authors.forename: Naoki
authors.initials: N
authors.lastname: Ishizuka
authors.forename: Akimasa
authors.initials: A
authors.lastname: Nakao
authors.forename: Hidemi
authors.initials: H
authors.lastname: Goto
authors.forename: Masato
authors.initials: M
authors.lastname: Nagino
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000601:surgery; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D020360:Neoadjuvant Therapy; D010071:Oxaloacetates; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000601:surgery; D012107:Research Design; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D010071:Oxaloacetates; D003841:Deoxycytidine; D000068258:Bevacizumab; D000069287:Capecitabine; D005472:Fluorouracil